Staff Directory

Dr Chris Austin Name: Dr Chris Austin
Lecturer (Science)
Phone
+612 9739 2255
Organisational Area
Faculty of Health Sciences
Department
School of Behavioural and Health Sciences (NSW)
Location
North Sydney
Building 532 - Tenison Woods House (8-20 Napier Street, North Sydney NSW 2060)-Level 7-Room 532.7.03
Biographical Information

Dr Christopher Austin (Ph.D.,Macquarie University) completed his Ph.D. in medicinal chemistry in 2006.  He has worked as a researcher/academic at the University of Sydney in diverse scientific fields including: Immunology, Pathology, Cancer Cell Biology, Organic Chemistry, Bioinorganic Chemistry and Higher Education.  His research interests lie at the interface between chemistry and biology, specifically the use of organic compounds to manipulate the human immune response.  He has published in Chemical CommunicationsThe Journal of Biological ChemistryThe American Journal of Pathology and Gene (amongst others).  He joined the Australian Catholic University as a Lecturer in the School of Science in 2016.

Publications

1              Austin, C. J. et al. Carborane-Containing Hydroxyamidine Scaffolds as Novel Inhibitors of Indoleamine 2, 3-Dioxygenase 1 (IDO1). Australian Journal of Chemistry 68, 1866-1870 (2016).

2              JU Kahlert, C. A., AJ Hall, A Rawal, JM Hook, LM Rendina, M Choucair. Site-specific synthesis of a hybrid boron-graphene salt. Chemical Communications 52, 1290-1292 (2015).

3              Austin, C. J. & Rendina, L. M. Targeting key dioxygenases in tryptophan&ndashkynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discovery Today 20, 609&ndash617 (2014).

4              Austin, C. J. et al. The first indoleamine-2, 3-dioxygenase-1 (IDO1) inhibitors containing carborane. Dalton Transactions 43, 10719-10724 (2014).

5              Aitken, J. B., Austin, C. J., Hunt, N. H., Ball, H. J. & Lay, P. A. The Fe-heme structure of met-indoleamine 2, 3-dioxygenase-2 determined by X-ray absorption fine structure. Biochemical and biophysical research communications 450, 25-29 (2014).

6              Sheridan, E. J. et al. Synchrotron X-ray fluorescence studies of a bromine-labelled cyclic RGD peptide interacting with individual tumor cells. Journal of Synchrotron Radiation 20, 226-233 (2013).

7              Kahlert, J., Austin, C., Kassiou, M. & Rendina, L. The Fifth Element in Drug Design: Boron in Medicinal Chemistry. Australian Journal of Chemistry 66, 1118&ndash1123 (2013).

8              Huang, M. et al. Molecular and Functional Alterations in a Mouse Cardiac Model of Friedreich Ataxia: Activation of the Integrated Stress Response, eIF2&alpha Phosphorylation, and the Induction of Downstream Targets. The American Journal of Pathology (2013).

9              Huang, M. et al. Hepcidin Bound to &alpha2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances its Activity at Reducing Serum Iron Levels. The Journal of Biological Chemistry (2013).

10           Austin, C. J. D., Kosim-Satyaputra, P., Smith, J. R., Willows, R. D. & Jamie, J. F. Mutation of Cysteine Residues Alters the Heme-Binding Pocket of Indoleamine 2,3-Dioxygenase-1. Biochemical and Biophysical Research Communications 436, 595-600 (2013).

11           Austin, C. J., Kahlert, J., Kassiou, M. & Rendina, L. M. The Translocator Protein (TSPO): A Novel Target for Cancer Chemotherapy. The International Journal of Biochemistry & Cell Biology 45, 1212-1216 (2013).

12           Yuasa, H. J., Ball, H. J., Austin, C. J. & Hunt, N. H. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 157, 10-15 (2010).

13           Austin, C. J. D. et al. Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2, 3-dioxygenase-2. Amino acids 39, 565-578 (2010).

14           Yuasa, H. J. et al. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases: IDOs from monotremes and marsupials. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 153, 137-144 (2009).

15           Ball, H. J., Yuasa, H. J., Austin, C. J., Weiser, S. & Hunt, N. H. Indoleamine 2, 3-dioxygenase-2 a new enzyme in the kynurenine pathway. The international journal of biochemistry & cell biology 41, 467-471 (2009).

16           Austin, C. J. et al. Mouse and human indoleamine 2, 3-dioxygenase display some distinct biochemical and structural properties. Amino Acids 36, 99-106 (2009).

17           Hunt, N. H. et al. in INTERNATIONAL JOURNAL FOR PARASITOLOGY.  S23-S24 (PERGAMON-ELSEVIER SCIENCE LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND).

18           Huttunen, J., Austin, C., Dawson, M., Roux, C. & Robertson, J. Physical evidence in drug intelligence, Part 1: rationale based on hierarchic distribution of drugs using pyrolysis gas chromatography&ndashmass spectrometry as an example. Australian Journal of Forensic Sciences 39, 93-106 (2007).

19           Ball, H. J. et al. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene 396, 203-213 (2007).

20           Poljak, A. et al. Inhibition of indoleamine 2, 3 dioxygenase activity by H2O2. Archives of biochemistry and biophysics 450, 9-19 (2006).

21           Austin, C. J. D. Structural and Ligand-Based Drug Design of Inhibitors of Indoleamine 2,3-Dioxygenase, Macquarie University, Australia, (2006).

22           Austin, C. J. et al. Optimised expression and purification of recombinant human indoleamine 2, 3-dioxygenase. Protein expression and purification 37, 392-398 (2004).

 

Research

Medicinal Chemistry, Drug Design, Protein Chemistry, Bioinorganic Chemistry, Higher Education

 

Have a question?

askacu

We're available 9am–5pm AEDT,
Monday to Friday

If you’ve got a question, our AskACU team has you covered. You can search FAQs, text us, email, live chat, call – whatever works for you.

Live chat with us now

Chat to our team for real-time
answers to your questions.

Launch live chat
Visit our FAQs page

Find answers to some commonly
asked questions.

See our FAQs